Zelluna Doses First Patient in Phase 1 Cancer Therapy Candidate Trial

11:48 AM EDT, 07/13/2026 (MT Newswires) -- Zelluna (ZLNA.OL) dosed the first patient in the phase 1 clinical trial evaluating ZI-MA4-1, its lead T-cell receptor-based natural killer cell therapy candidate. The study, conducted in the UK, is evaluating the safety, tolerability, and preliminary anti-tumor activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumors, according to a Monday filing. The Norwegian biopharmaceutical company said it is on track to come up with initial clinical data halfway through the year.